Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Arrowhead Pharmaceuticals reported fiscal year 2022 results, achieving $243.2 million in revenue, up from $138.3 million in 2021. The company incurred a net loss of $172.7 million or $1.67 per diluted share. Operating expenses rose to $421.7 million compared to $287.3 million the prior year. Despite financial challenges, significant progress was made in clinical trials, with promising interim data on ARO-APOC3 and ARO-ANG3. The balance sheet was bolstered by a $250 million royalty sale and potential future earnings from Amgen.
- Revenue increased by 76% from $138.3 million in 2021 to $243.2 million in 2022.
- Successful full enrollment for Phase 2 studies of ARO-APOC3 and ARO-ANG3.
- Impressive interim data showing 86% triglyceride reduction with ARO-APOC3.
- Strengthened balance sheet with a $250 million royalty sale to Royalty Pharma.
- Net loss increased to $172.7 million from $140.8 million in the previous year.
- Operating expenses rose significantly to $421.7 million, resulting in an operating loss of $178.5 million.
- Conference Call and Webcast Today,
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI9d277550044a4f44bfc335d52e38d268. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Selected Recent Events
-
Presented interim data on the cardiometabolic pipeline in three late-breaking oral presentations at the
American Heart Association (AHA) Scientific Sessions 2022 and at a virtual analyst and investor event. Key results included the following:-
ARO-APOC3, an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with cardiovascular disease, severe hypertriglyceridemia (SHTG), and familial chylomicronemia syndrome (FCS), decreased triglycerides by
86% , and non-HDL-C by45% while increasing HDL-C by99% in patients with severe hypertriglyceridemia -
ARO-ANG3, investigational RNAi therapeutic designed to silence the hepatic expression of angiopoietin-like protein 3 (ANGPTL3) being developed as a treatment for patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH), decreased triglycerides by
59% , LDL-C by32% , and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia -
Olpasiran, which was originally developed by Arrowhead using its proprietary Targeted RNAi Molecule (TRiM™) platform and licensed to Amgen in 2016 and is designed to lower levels of lipoprotein(a) (Lp(a)), a genetically-determined independent risk factor for cardiovascular disease, reduced Lp(a) levels by more than
95% in patients with established atherosclerotic cardiovascular disease. These data were simultaneously published in theNew England Journal of Medicine (NEJM)
-
ARO-APOC3, an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with cardiovascular disease, severe hypertriglyceridemia (SHTG), and familial chylomicronemia syndrome (FCS), decreased triglycerides by
-
Reached full enrollment for Phase 2 studies of cardiometabolic candidates ARO-APOC3 and ARO-ANG3, including SHASTA-2, MUIR,
ARCHES -2, andGATEWAY -
Strengthened the balance sheet with the sale of Arrowhead’s royalty interest in olpasiran to Royalty Pharma for:
-
in cash upfront$250 million -
Up to
in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones$160 million -
Retained rights to
in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out-licensing agreement$400 million
-
-
Initiated Phase 1/2a clinical studies for two new investigational medicines designed to treat various muco-obstructive and inflammatory pulmonary conditions
- ARO-MUC5AC, an investigational RNAi therapeutic designed to inhibit the production of mucin 5AC (MUC5AC)
- ARO-RAGE, an investigational RNAi therapeutic designed to inhibit the production of Receptor for Advanced Glycation End products (RAGE)
- Initiated a Phase 1/2a clinical trial of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), with dosing to begin soon
Selected Fiscal 2022 Year End Financial Results
|
||||||||
CONSOLIDATED CONDENSED FINANCIAL INFORMATION |
||||||||
(in thousands, except per share amounts) |
||||||||
|
|
|
|
|
|
|
|
|
|
|
Year Ended |
||||||
OPERATING SUMMARY |
|
2022 |
|
2021 |
||||
REVENUE |
$ |
243,231 |
|
$ |
138,287 |
|
||
OPERATING EXPENSES |
|
|
|
|
||||
Research and development |
|
297,307 |
|
|
206,342 |
|
||
General and administrative expenses |
|
124,431 |
|
|
80,981 |
|
||
TOTAL OPERATING EXPENSES |
|
421,738 |
|
|
287,323 |
|
||
OPERATING INCOME (LOSS) |
|
(178,507 |
) |
|
(149,036 |
) |
||
OTHER INCOME/(EXPENSE) |
|
5,798 |
|
|
8,190 |
|
||
NET INCOME (LOSS) |
$ |
(172,709 |
) |
$ |
(140,846 |
) |
||
|
|
|
|
|
||||
NET INCOME (LOSS) PER SHARE (DILUTED) |
$ |
(1.67 |
) |
$ |
(1.36 |
) |
||
WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED) |
|
105,426 |
|
|
103,745 |
|
||
|
|
|
|
|||||
FINANCIAL POSITION SUMMARY |
|
|
||||||
|
2022 |
2021 |
||||||
CASH AND CASH EQUIVALENTS |
$ |
108,005 |
|
$ |
184,434 |
|
||
SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES |
|
268,391 |
|
|
183,355 |
|
||
|
|
105,872 |
|
|
245,595 |
|
||
TOTAL CASH RESOURCES (CASH AND INVESTMENTS) |
|
482,268 |
|
|
613,384 |
|
||
OTHER ASSETS |
|
209,671 |
|
|
96,764 |
|
||
TOTAL ASSETS |
|
691,939 |
|
|
710,148 |
|
||
TOTAL CURRENT DEFERRED REVENUE |
|
74,099 |
|
|
111,055 |
|
||
TOTAL LONG-TERM DEFERRED REVENUE |
|
55,950 |
|
|
131,495 |
|
||
OTHER LIABILITIES |
|
143,551 |
|
|
58,776 |
|
||
TOTAL LIABILITIES |
|
273,600 |
|
|
301,326 |
|
||
TOTAL STOCKHOLDERS' EQUITY |
|
418,339 |
|
|
408,822 |
|
||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
691,939 |
|
$ |
710,148 |
|
||
|
|
|
|
|
||||
SHARES OUTSTANDING |
|
105,960 |
|
|
104,327 |
|
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005710/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com
Source:
FAQ
What were Arrowhead Pharmaceuticals' financial results for fiscal year 2022?
What is the development status of Arrowhead's cardiometabolic pipeline?
How did Arrowhead Pharmaceuticals' expenses change in fiscal year 2022?